NO20082474L - Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav - Google Patents

Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav

Info

Publication number
NO20082474L
NO20082474L NO20082474A NO20082474A NO20082474L NO 20082474 L NO20082474 L NO 20082474L NO 20082474 A NO20082474 A NO 20082474A NO 20082474 A NO20082474 A NO 20082474A NO 20082474 L NO20082474 L NO 20082474L
Authority
NO
Norway
Prior art keywords
compound
sulfonate
preparation
montelukast
prepared
Prior art date
Application number
NO20082474A
Other languages
English (en)
Inventor
Marti Bartra Sanmarti
Yolanda Gasanz Guillen
Laura Coppi
Montserrat Monsalva Llagostera
Pedro Talavera Escasany
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of NO20082474L publication Critical patent/NO20082474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den innbefatter en fremstillingsfremgangsmåte for Montelukast fra en ny intermediatforbindelse med formel (VI) som på forhånd er fremstilt ved omsetting av det korresponderende sulfonatet med l-(merkaptometyl)cyklopropyl)metanol. Forbindelse (VI) omsettes med en Grignard reaktant for å omdanne estergruppen til en tertiær alkohol, fulgt av omdanning av den primære alkoholen til et sulfonat, substitusjon av sulfonatgruppen med en cyanogruppe og til slutt omdanne cyanoforbindelsen til karboksylsyreforbindelsen ved en hydrolysereaksjon for å gi Montelukast. Montelukast kan også fremstilles ved en hydrolysereaksjon med det korresponderende amidet. Den innbefatter også nye mtermediatforbindelser anvendelige i slike fremstillingfremgangsmåter.
NO20082474A 2005-11-04 2008-06-02 Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav NO20082474L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73355305P 2005-11-04 2005-11-04
EP05110348A EP1783117A1 (en) 2005-11-04 2005-11-04 Process for the preparation of a leukotriene antagonist and intermediates thereof
PCT/EP2006/068052 WO2007051828A2 (en) 2005-11-04 2006-11-03 Process for the preparation of a leukotriene antagonist and intermediates thereof

Publications (1)

Publication Number Publication Date
NO20082474L true NO20082474L (no) 2008-06-02

Family

ID=36169064

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082474A NO20082474L (no) 2005-11-04 2008-06-02 Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav

Country Status (11)

Country Link
US (1) US20080306270A1 (no)
EP (2) EP1783117A1 (no)
JP (1) JP2009514927A (no)
KR (1) KR20080064968A (no)
CN (1) CN101321732B (no)
AU (1) AU2006310536A1 (no)
CA (1) CA2627098A1 (no)
NO (1) NO20082474L (no)
RU (1) RU2402532C2 (no)
WO (1) WO2007051828A2 (no)
ZA (1) ZA200803761B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213177A (zh) 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
CN103539714A (zh) * 2012-07-16 2014-01-29 上海朴颐化学科技有限公司 1-巯甲基环丙基乙酸及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts

Also Published As

Publication number Publication date
CN101321732A (zh) 2008-12-10
CN101321732B (zh) 2011-04-13
WO2007051828A2 (en) 2007-05-10
EP1948611A2 (en) 2008-07-30
CA2627098A1 (en) 2007-05-10
WO2007051828A3 (en) 2007-08-23
EP1948611B1 (en) 2012-05-23
EP1783117A1 (en) 2007-05-09
ZA200803761B (en) 2009-09-30
RU2008122367A (ru) 2009-12-10
JP2009514927A (ja) 2009-04-09
RU2402532C2 (ru) 2010-10-27
US20080306270A1 (en) 2008-12-11
KR20080064968A (ko) 2008-07-10
AU2006310536A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
CN111875538B (zh) 一种匹伐他汀叔丁酯的合成方法
JP2009533369A5 (no)
JP2012251113A5 (no)
JP2011098951A (ja) フェニルアセトアミド化合物の製造方法
TW200726754A (en) Chemical process
TW201035052A (en) Process for manufacturing substituted 5-methoxymethylpyridine-2,3-dicarboxylic acid derivatives
NO20080080L (no) Organiske forbindelser
WO2007051828A3 (en) Process for the preparation of a leukotriene antagonist and intermediates thereof
CN100384801C (zh) (e)-3,5-二甲氧基-4＇-羟基二苯乙烯的合成方法
TW202340160A (zh) 製備異㗁唑啉－５，５－乙烯基羧酸衍生物之方法
US9533956B2 (en) Method of manufacturing pyridazinone compound
CN111072630A (zh) 一种溴代吡唑类化合物中间体的制备方法与应用
US7619095B2 (en) Process for the preparation of indolone derivative
RU2012118499A (ru) Способ получения пиразинонового ингибитора тромбина и промежуточных соединений для его получения
WO2011004242A3 (en) An improved process for the preparation of dutasteride
US20090187020A1 (en) Process And Intermediate For Preparation Of Donepezil
WO2011096697A3 (en) Process for preparing voriconazole by using new intermediates
JP5001144B2 (ja) ２−イソプロペニル−５−メチル−４−ヘキセン−１−イル３−メチル−２−ブテノアートの製造方法
RU2529025C1 (ru) Способ получения производных 2,2-адамантиленспирооксирана
CN103588755B (zh) Neratinib的制备方法
JP5181560B2 (ja) スピロアンモニウム四フッ化ホウ素酸塩化合物の製法
CN117586177A (zh) 一种阿维巴坦中间体的制备方法
TW387881B (en) 3-(isoxazol-5-yl)-substituted benzoic acid derivative and method for production thereof
CN101172960B (zh) 一种卡比多巴中间体的绿色合成方法
WO2006024630A8 (en) Process for the production of [2- (4-fluoro-benzyl) -phenyl] -acetic acid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application